

# ABOUT SKIMS-BIO



## Contact

*Hyo Seon Ma / Chang-Keun Kim*

Room 101, 24-1 Sanggye-ro 10-gil

Nowon-gu, Seoul

(Sanggye-dong, Insoo Building,

Sanggye Paik Hospital)

Republic of Korea

Tel: +82-2-950-8832

[mhs2410@nate.com](mailto:mhs2410@nate.com)

[kimck@paik.ac.kr](mailto:kimck@paik.ac.kr)

## *Company Introduction/Overview*

SKIMS-BIO is a biotechnology company founded and based in Seoul, South Korea, specializing in the research, development, and production of biomarker-based allergy diagnostic solutions. The company is composed of a highly specialized team that focuses on developing both cost-effective and precise in-vitro (IVD) diagnostic kits that achieve early, reliable detection of allergic diseases while remaining economically viable for healthcare systems. In doing so, we aim to bridge modernization and accessibility.

Tailoring our expansion to meet global market needs, we pride ourselves as a leader in the IVD industry, especially in an area as unexplored as early asthma diagnosis. The company is dedicated to advancing accurate, affordable, and clinically practical diagnostic technologies for improved patient care. We hope to expand this vision to foreign markets, as we develop plans to collaborate with foreign companies for global distribution. We heavily prioritize continuous growth as a global biotechnology innovator.

## *Mission*

SKIMS-BIO is guided by the principle of Ui-Chang-Geun-Seong (醫昌根盛)--a four-character idiom that means to contribute to society as a prosperous medical innovator with deep, unwavering roots. We strive to build solutions that are not only clinically precise and economically accessible, but also to serve the public in integrity, responsibility, and long-term dedication to public health.

This philosophy reflects our belief that true innovation must be both impactful and enduring: rooted in foundations of dedication and scientific advancement while continuously growing to serve society through improved diagnostic accuracy, broader accessibility, and meaningful contributions to global healthcare.

A foundational aspect of our vision is to establish SKIMS-BIO as a leading biotechnology innovator in the allergy and asthma sector and strategically form commercial partnerships within Korea, the broader Asia-Pacific region, and further.

## *Core Technical Expertise*

SKIMS-BIO's expertise includes:

- Biomarker-based allergy diagnostics
- Development of the K-EDN kits, consisting of the ELISA and the Rapid kit
- Translation of research technologies into commercial medical products
- Regulatory strategy and approval processes through the Korean Food and Drug Administration (KFDA / MFDS)

## *Products in Development*

The K-EDN (Eosinophil-Derived Neurotoxin) Diagnostic Kit is a blood test that measures the level of EDN, a protein released by eosinophils, to help assess asthma and allergic inflammation. It is especially useful in children who cannot easily undergo lung function tests, and can also be used to monitor treatment response. It is a product of SKIMS-BIO that has reached completion and is undergoing testing services in Korea through the Green Cross Medical Foundation. With the K-EDN kit, the top priorities are its affordability and accessibility, resulting in an ability for consistent monitoring.

Given that some overlying issues with pediatric asthma are late diagnosis and a neglect for decreasing pulmonary function, early detection is crucial. We have designed the kit so that it is capable of diagnosing premature conditions, a vital characteristic for timely treatment and full recovery. Our most reliable and prominent benefits include affordability, accuracy, and promptness. These qualities make the K-EDN kit valuable in all age groups, especially in the intergenerational population.

The K-EDN Diagnostics consist of two kits:

- K-EDN ELISA Kit Immunoassay Reagents
  - For clinical laboratory use
  - High analytical accuracy
  - Capacity to process up to 80 samples simultaneously
- K-EDN Rapid Kit POCT (Point-of-Care Testing) Diagnostics
  - For primary screenings in outpatient clinics
  - Produces results in 10 minutes with a single drop of blood

These products have been developed to meet international standards while maintaining cost efficiency for widespread clinical adoption.

## *Partnership Objective with Agnitio*

Observing an alignment in mission, scientific innovation, and commitment to patient-centered care, SKIMS-BIO seeks a strategic partnership with Agnitio. We believe that a collaboration between Agnitio and SKIMS-BIO can accelerate the boom of cutting-edge allergy diagnostic technologies within the clinical sphere. We plan on combining Agnitio's advanced products with SKIMS-BIO's expertise in regulatory navigation, localization, and market execution within Korea. This collaboration is intended to create a pathway for Agnitio's technologies to successfully penetrate and scale within the Korean market, while advancing shared goals of improving patient outcomes and fostering long-term innovation in allergy / asthma care.

SKIMS-BIO seeks a strategic partnership with Agnitio to:

- Support regulatory approval of Agnitio's allergy diagnostic technologies through the Korean Food and Drug Administration (KFDA/MFDS)
- Secure patent registration and intellect property protection within Korea
- Localize Agnitio's products for regulatory, clinical, and commercial alignment with the Korean healthcare system
- Facilitate market entry and commercialization strategies that ensure sustainable growth and adoption

## *Why SKIMS-BIO*

The successful advancement of the K-EDN diagnostic platform represents a key milestone in SKIMS-BIO's growth as a biotechnology company, demonstrating the company's ability to practically apply biomarker research into diagnostic solutions. Through the design and advancement of both the K-EDN ELISA and Rapid Diagnostics Kits, SKIMS-BIO has established a strong foundation in assay development, product optimization, and diagnostic system integration.

Furthermore, SKIMS-BIO offers, not only product development, but also strategic market integration, expanding the company's area of expertise from scientific development to commercialization. This trait significantly reduces barriers for international companies.

SKIMS-BIO's strengths include:

- Identifying and applying clinically relevant allergy biomarkers
- Engineering both laboratory-based and point-of-care diagnostic formats
- Balancing scientific accuracy with cost efficiency and accessibility
- Advancing products toward regulatory readiness and commercialization

SKIMS-BIO's experience positions the company as a capable and reliable partner for international companies seeking not only scientific collaboration, but also strategic execution within the Korean healthcare market. The company bridges innovation and implementation, transforming concepts into structured scalable solutions that meet real-world clinical needs.

## *Closing Statement*

Through the development of the K-EDN kit, SKIMS-BIO has been building a strong operational and scientific framework for diagnostic innovation. As a partner, SKIMS-BIO brings stability, precision, and long-term commitment. The company is positioned to support sustained product growth, regulatory compliance, and market adaptation beyond initial approval, ensuring that Agnitio's diagnostic technologies achieve lasting clinical and commercial success.